Institutional investors increase stakes in L3Harris and Nurix Therapeutics

Recent SEC filings reveal significant changes in institutional holdings for L3Harris Technologies Inc and Nurix Therapeutics, Inc.

NewEdge Advisors LLC increased its stake in L3Harris Technologies Inc by 25.7% during the first quarter, bringing its total holdings to 38,662 shares valued at approximately $13.3 million. Other institutional investors also adjusted their positions, including the Swiss National Bank, which increased its stake by 7.1%, and Vanguard Group Inc., which holds over 23 million shares.

Dimensional Fund Advisors LP grew its position in Nurix Therapeutics, Inc. by 81.1% in the first quarter, purchasing an additional 349,710 shares. This brought the firm's total ownership to 780,696 shares, valued at roughly $12 million. Additionally, several research analysts have recently updated their outlooks on Nurix, with firms such as HC Wainwright and UBS Group raising price targets.